Recruiting × Kidney Neoplasms × Dermatologic × Clear all
NCT04485013 2026-02-18

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

Tizona Therapeutics, Inc

Phase 1 Recruiting
240 enrolled
NCT07410676 2026-02-18

EBNK-ST-001

Essen Biotech

Phase 1/2 Recruiting
83 enrolled
NCT02012699 2026-01-22

iCaRe2

University of Nebraska

Recruiting
999,999 enrolled
NCT06673329 2025-05-14

Brodalumab in the Treatment of Immune-Related Adverse Events

Columbia University

Phase 1 Recruiting
11 enrolled